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Background
The first antibody-inducing HIV-1 vaccines are unlikely
to protect against all HIV-1 isolates. There is thus a
danger that a vaccine will select for HIV-1 viruses that
are highly resistant to antibody-mediated neutralization.
We sought to identify and characterize such viruses.
Methods
A diverse panel of 24 HIV-1 pseudoviruses was tested for
neutralization resistance using two sets of samples from
ARV-naive HIV-1-infected individuals selected for good
neutralizers: sera from South Africa donors (n=68, infected
>1 year, subtype C predominant area) and CRF02_AG-
infected plasma samples from Cameroon donors (n=12,
good neutralizers selected from 22 samples).
Results
Sensitivity to South Africa sera by subtype was
C>B≈CRF02_AG>A. Importantly, and in contrast to pre-
vious reports, CRF02_AG plasma neutralized CRF02_AG
viruses better than other panel viruses (“within-subtype
neutralization”). This included three (257-31, 251-18 and
33-7) of five CRF02_AG viruses previously designated as
tier 3 (most resistant). This within-subtype neutralization
testing showed that the other two tier 3 CRF02_AG
panel viruses, 253-11 and 278-50 were highly resistant.
Most CRF02_AG viruses, including 253-11 and 278-50
were sensitive to two membrane proximal external region
(MPER)-specific monoclonal antibodies and soluble CD4
(sCD4), suggesting targets for neutralization of even
these highly resistant viruses. This information may help
design a global HIV-1 vaccine. We also propose testing
viruses with within-subtype samples selected for good
neutralizers in order to evaluate their neutralization
resistance.
Conclusion
Some but not all CRF02_AG viruses are sensitive to neu-
tralisation by CRF02_AG-derived plasma, even though
most are previously reported as highly resistant (Tier 3).
Further work is necessary to properly characterize such
Tier 3 viruses. If research focus is not placed on such
resistant viruses, a future partially effective HIV-1 vaccine
may select for them.
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